Concord Biotech Ltd
Concord Biotech Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
FY '26 growth expected below historical averages due to first-half challenges; optimistic for Q4 improvement. FY '26 growth expected below historical averages due to H1 challenges but Q3 & Q4 show improving momentum.
From Concord Biotech Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- FY '26 growth expected below historical averages due to first-half challenges; optimistic for Q4 improvement.
- Medium-term growth drivers include:
- Injectables contributing around 6% growth over the next 3-5 years.
- CDMO segment growth due to global shift favoring India.
- Combined baseline growth (API and formulations) around 18%, with injectables and CDMO potentially raising CAGR to ~25% over time.
- Expansion plans involve new product launches, increasing market share in anti-infectives, antifungal, and oncology segments.
- Non-immunosuppressant products expected to gain market share gradually, similar to immunosuppressants, focusing on complex, niche products with limited competition.
- Moderate volume-led growth in API business; pricing remains stable, with limited discounts.
2 more points management made on revenue & sales performance
Profitability & Margins
See what Concord Biotech Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Maintenance capex for FY '26 and going forward is around INR 30-40 crores annually, not the earlier mentioned INR 100-150 crores.
- Additional capex beyond maintenance is being incurred for newer projects linked to customer opportunities and growth, contributing to a blended capex of INR 100-150 crores annually.
- The company is investing in commercialization of new injectable facilities and subsidiaries in the U.S. market, with the injectable facility having a peak revenue potential of approximately INR 600 crores.
- Concord Lifegen Limited, a wholly owned subsidiary, was incorporated to strengthen marketing, sales, and distribution in India.
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Concord Biotech Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The transcript does not provide explicit data on the current or expected order book or pending orders for Concord Biotech Limited.
- However, it mentions increased engagement and advanced discussions around second source supply opportunities post-clarity on U.S. tariffs, indicating a growing pipeline of potential orders.
- Discussions are underway with both existing customers and new innovator/generic players, with expectations of commercializing at least one new project in the near term.
- The company is optimistic about growth momentum entering Q4 FY '26 and expects improved performance driven by new product launches and CDMO partnerships.
2 more points management made on order book & pipeline
Concord Biotech Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹278 Cr, net profit ₹68 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Concord Biotech's management said in earlier quarters
- Q3 FY25 earnings call analysis →
- Q1 FY27 earnings call analysis →
- Q2 FY26 earnings call analysis →
- Q4 FY26 earnings call analysis →
- Q1 FY26 earnings call →
- Q4 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- RPG Life Sciences Ltd (Q3 FY26)
180.0 crore, up from Rs. Key concall takeaways from RPG Life Sciences Ltd's Q3 FY26 earnings call — and how it ranks against sector peers.
- SMS Pharmaceuticals Ltd (Q3 FY26)
Q3FY26 Revenue from Operations: ₹210.45 crore, up 21% YoY (from ₹173.35 crore in Q3FY25) [Page 27] . Key concall takeaways from SMS Pharmaceuticals Ltd's Q3…
- Morepen Laboratories Ltd (Q3 FY26)
488 crores, up 17% from Q3 FY25 Rs. Key concall takeaways from Morepen Laboratories Ltd's Q3 FY26 earnings call — and how it ranks against sector peers.
- Jubilant Pharmova Ltd (Q3 FY26)
2,143 Cr., up from Rs. Key concall takeaways from Jubilant Pharmova Ltd's Q3 FY26 earnings call — and how it ranks against sector peers.
Frequently Asked Questions
What were Concord Biotech Ltd Q3 FY26 results?
FY '26 growth expected below historical averages due to first-half challenges; optimistic for Q4 improvement. FY '26 growth expected below historical averages due to H1 challenges but Q3 & Q4 show improving momentum.
What is Concord Biotech Ltd share price analysis?
Concord Biotech Ltd currently shows a neutral. The stock trades at a P/E of 51.0 with a market cap of ₹14,489 Cr. Investors should review the full earnings analysis for detailed insights.
Is Concord Biotech Ltd planning capital expenditure?
Maintenance capex for FY '26 and going forward is around INR 30-40 crores annually, not the earlier mentioned INR 100-150 crores.
Keep Concord Biotech Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.